Brainy

Some have been lamenting the news that many large pharmaceutical companies are terminating R&D in Central Nervous System (CNS) diseases. CNS has always been the holy grail of medicine – some seeking to define the brain and others attempting to showcase just the shortcomings of it. Some stood perplexed at the prospect of unpredictable side effects of designer drugs that are highly selective and others took a sledgehammer to the neuron network to numb it, with no tangible effects. In either cas...